NASDAQ:HUGE - FSD Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 554.76 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.68
▲ +0.05 (3.07%)

This chart shows the closing price for HUGE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New FSD Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HUGE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HUGE

Analyst Price Target is $11.00
▲ +554.76% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for FSD Pharma in the last 3 months. The average price target is $11.00, with a high forecast of $11.00 and a low forecast of $11.00. The average price target represents a 554.76% upside from the last price of $1.68.

This chart shows the closing price for HUGE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in FSD Pharma.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/29/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/20/2020Brookline Capital ManagementInitiated CoverageBuy$11.00N/A
(Data available from 7/28/2016 forward)
FSD Pharma logo
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD 201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also develops drugs for the treatment of pain, inflammation, and neurological disorders. It has license agreements with Epitech Group SpA.; and with Innovet Italia S.R.L. to develop veterinary drugs for the treatment of gastro-intestinal diseases in dogs and cats. The company was founded in 1998 and is headquartered in Toronto, Canada.
Read More

Today's Range

Now: $1.68
Low: $1.67
High: $1.69

50 Day Range

MA: $1.75
Low: $1.51
High: $2.13

52 Week Range

Now: $1.68
Low: $1.28
High: $6.87

Volume

1,331 shs

Average Volume

2,066,498 shs

Market Capitalization

$60.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Frequently Asked Questions

What sell-side analysts currently cover shares of FSD Pharma?

The following Wall Street research analysts have issued reports on FSD Pharma in the last year: Brookline Capital Management.
View the latest analyst ratings for HUGE.

What is the current price target for FSD Pharma?

1 Wall Street analysts have set twelve-month price targets for FSD Pharma in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 554.8%. Brookline Capital Management has the highest price target set, predicting HUGE will reach $11.00 in the next twelve months. Brookline Capital Management has the lowest price target set, forecasting a price of $11.00 for FSD Pharma in the next year.
View the latest price targets for HUGE.

What is the current consensus analyst rating for FSD Pharma?

FSD Pharma currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HUGE will outperform the market and that investors should add to their positions of FSD Pharma.
View the latest ratings for HUGE.

What other companies compete with FSD Pharma?

How do I contact FSD Pharma's investor relations team?

FSD Pharma's physical mailing address is 520 WILLIAM STREET, COBOURG A6, K9A 3A5. The company's listed phone number is (416) 854-8884 and its investor relations email address is [email protected] The official website for FSD Pharma is fsdpharma.com.